Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease.
about
Modulation of Pathways Underlying Distinct Cell Death Mechanisms in Two Human Lung Cancer Cell Lines in Response to SN1 Methylating Agents Treatment.Temozolomide-perillyl alcohol conjugate induced reactive oxygen species accumulation contributes to its cytotoxicity against non-small cell lung cancer.Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer.Cell cycle effects and increased adduct formation by temozolomide enhance the effect of cytotoxic and targeted agents in lung cancer cell lines.F2A sequence linking MGMT(P140K) and MDR1 in a bicistronic lentiviral vector enables efficient chemoprotection of haematopoietic stem cells.
P2860
Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Phase I trial of weekly doceta ...... ients with metastatic disease.
@ast
Phase I trial of weekly doceta ...... ients with metastatic disease.
@en
type
label
Phase I trial of weekly doceta ...... ients with metastatic disease.
@ast
Phase I trial of weekly doceta ...... ients with metastatic disease.
@en
prefLabel
Phase I trial of weekly doceta ...... ients with metastatic disease.
@ast
Phase I trial of weekly doceta ...... ients with metastatic disease.
@en
P2093
P1476
Phase I trial of weekly doceta ...... ients with metastatic disease.
@en
P2093
I Tamaskar
R M Bukowski
P2888
P304
P356
10.1007/S10637-008-9153-0
P577
2008-07-15T00:00:00Z
P6179
1003700544